Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates

Medical Mycology

Volumn 51, Issue 1, 2013, Pages 60-65

  Oz, Yasemin ^a   Kiremitci, Abdurrahman ^a   Dag, Ilknur ^a   Metintas, Selma ^a   Kiraz, Nuri ^b  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Candida krusei; Caspofungin; Combination; Postantifungal effect

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA KRUSEI; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 84870915192     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.697198     Document Type: Article

References (17)

1. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493- 2499.
2. Lockhart SR, Wagner D, Iqbal N, et al. Comparison of i n vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol 2011; 49: 2404-2410.
3. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast, M27-A3, 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
4. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44: 1108-1111.
5. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of Etest, chequerboard dilution and timekill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002; 49: 345- 351.
6. Roling EE, Klepser ME, Wasson A, et al. Antifungal activities of fl uconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002; 43: 13-17.
7. Pfaller MA, Diekema DJ, Gibbs DL, et al. Global Antifungal Surveillance Group. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: Geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46: 515-521.
8. Clancy CJ, Huang H, Cheng S, Derendorf H, Nguyen MH. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother 2006; 50: 2569-2572.
9. Di Bonaventura G, Spedicato I, Picciani C, D' Antonio D, Piccolomini R. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fl uconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob Agents Chemother 2004; 48: 4453-4456.
10. Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, Chandrasekar PH. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004; 53: 386-389.
11. Chryssanthou E, Cars O, Sjö lin J. New automated method for determining postantifungal effect of amphotericin B against Candida species: Effects of concentration, exposure time, and area under the curve. Antimicrob Agents Chemother 2002; 46: 4016-4018.
12. Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 2004; 48: 970-978.
13. Li H, Lu Q, Wan Z, Zhang J. I n vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii. Int J Antimicrob Agents 2010; 35: 550-552.
14. MacCallum DM, Whyte JA, Odds FC. Effi cacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005; 49: 3697-3701.
15. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: Review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37: P188-224.
16. Kiraz N, Dag I, Yamac M, e t al. Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: Comparison of disk diffusion, Etest, and time-kill methods. Antimicrob Agents Chemother 2009; 53: 788-790.
17. Kiraz N, Dag I, Yamac M, e t al. Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest and disk diffusion methods. Antimicrob Agents Chemother 2010; 54: 2244-2247.